VirMedica’s dynamic leadership team is a unique convergence of recognized leaders and experts across several disciplines with a variety of executive-level experience and complementary competences critical to redefining the patient access ecosystem for biopharmaceutical products, including corporate strategy, business development, commercialization, sales, manufacturing, pharmacy services, benefits and reimbursement, and manufacturing.
Phil has been president, chief executive officer and a director since April 2016 and is a seasoned industry leader with more than 35 years of executive management and leadership experience across a wide range of enterprise solutions. For the past two decades, Phil has focused on driving innovation and accelerating drug development for the life sciences industry. Most recently, Phil served as president and chief executive officer of PHT Corporation, a leading provider of electronic clinical outcome assessments solutions for the biopharmaceutical industry. The company’s pioneering work and thought leadership propelled the rapid adoption of electronic patient-reported outcomes in clinical trials worldwide. Prior executive management positions included serving as President of eXcelon Corporation and as President and CEO of Clinsoft. Earlier in his career, Phil held roles of increasing responsibility at Bolt, Beranek & Neumann, Interleaf, Inc., Oracle Corporation and Digital Equipment Corporation. Phil has been recognized for his achievements by Ernst & Young as a two-time ‘Entrepreneur of the Year’ finalist, has been named to PharmaVoice’s ‘100 Most Inspirational People in Life Sciences’ and as a ‘Tech Luminary of the Year’ by Mass High Tech and The Boston Business Journal. Phil holds a B.S. in Operations Research and Industrial Engineering and a Master of Engineering degree from Cornell University.
John joined VirMedica in May 2016. In his role as Chief Financial Officer (CFO), John is responsible for the company’s financial operations, business contracts and human resources. His professional career in finance spans more than 30 years and includes deep expertise in profitability enhancement, mergers and acquisitions, investor relations and financial controls/management. John’s industry background includes senior financial management positions in semiconductor testing equipment, biotechnology, healthcare technology and globalization services. Prior to joining VirMedica, John was the CFO for PHT Corporation, a leading provider of mobile technologies designed to capture patient data in clinical trials. During his tenure, he led the due diligence team that resulted in the successful sale of PHT Corporation to eResearch Technologies. Previous CFO engagements include CRF, Inc., Organogenesis, Inc., and Intl.com, among others. John began his career with Price Waterhouse in Boston where he served as Audit Manager. He holds an MBA from New Mexico State University.
Richard (Rich) was appointed to the position of Vice President of Client Services in May 2016. Rich leads all service teams engaged in the delivery of VirMedica’s technology solutions. Recognized as an astute and collaborative business partner, Rich is known for transforming customer support operations, professional services and managed hosting organizations to be customer focused, accountable and results oriented. Rich brings more than 30 years of leadership experience in SaaS and cloud-based software operations. Most recently, he served as Senior Vice President at Global Service Delivery, Data Intensity, a leading supplier of cloud-based and remote managed solutions for the Oracle suite. Prior to Data Intensity, Rich was Vice President product support/cloud enablement for Oracle, where he was responsible for global customer support for Oracle’s HSGBU (Health Sciences Global Business Unit). Previous to that, he was Vice President of Customer Operations at Phase Forward, which was acquired by Oracle in 2010. While at Phase Forward, Rich was responsible for all infrastructure and SaaS operations, along with global support and customer care engagement management teams supporting several leading international pharmaceutical and biotechnology companies. Rich received his B.S. in Business Administration from Fitchburg State College and his MBA from Northeastern University.
Greg has served as CCO of VirMedica since January 2015 and brings over 25 years of expertise in the insurance reimbursement and benefits management arena. Prior to joining VirMedica, Greg founded TransEngen, Inc., a leading provider of automated, real-time benefits verification service. As chief commercial officer of VirMedica, Greg oversees product strategy and commercialization efforts for the Company’s integrated platform for automated HUB services, patient case management and specialty pharmacy operations. Greg has previously served as chief operating officer at Aon’s National Healthcare Practice and HealthMarket. Greg holds a B.A. in Economics from Harvard University.
John has been Chairman since November 2015 and is a recognized leader in the biopharmaceutical industry, bringing more than 30 years of experience at leading global organizations – including Johnson & Johnson, Eli Lilly & Company, ImClone and Pfizer. John works closely with VirMedica’s seasoned leadership and shares his recognized industry expertise and entrepreneurial spirit with the team. He currently serves as chairman of Strongbridge Biopharma plc, lead independent director of Sucampo Pharmaceuticals, Inc., and as a member of the board of directors of Cempra Pharmaceuticals, Inc., Histogenics Corporation and Portola Pharmaceuticals, Inc. He previously served as a member of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry Organizations (BIO), and BioNJ. John holds a B.S. from the East Stroudsburg University of Pennsylvania.
Dean, president of D2 Pharma Consulting, LLC was appointed to the board of directors in January 2015. He brings more than 25 years of strategic sales, marketing and management experience across both the consumer product and pharmaceutical arenas that spans several Fortune 500 organizations, including Express Scripts, Cardinal Health and U.S. Healthcare. Dean is a co-founder of D2 Pharma Consulting, a firm which provides strategic outsourced solutions for the commercialization, distribution and marketing of pharmaceuticals, medical devices and biologic medications. Dean has worked with over 200 companies in developing strategic and tactical solutions in the areas of product distribution and reimbursement. He has previously served as president of the not-for-profit Regulatory Harmonization Institute and currently serves on the board of trustees of STAGES St. Louis. Dean holds a B.A. from the University of Oklahoma and a MBA from the Keller Graduate School of Management.
Appointed in January 2015, David is general partner at Petra Capital Partners and has nearly 20 years of experience in private equity and mergers and acquisitions in the healthcare, information technology and business services sectors. David currently serves on the board of directors for Clinipace Worldwide, Lineagen, New Century Hospice, Opportune IT Healthcare Solutions, SUN Behavioral Health and Urgent Team. He previously served on the board of directors for many successful growth companies, including SpecialtyCare (sold to American Securities), US Healthworks (sold to Dignity Health), Televox Software (sold to West Corp.), Appriss (sold to Bain Capital), Synhrgy (sold to Mercer), Nuvox Communications (sold to Windstream) and Salveo Specialty Pharmacy (sold to Catamaran). David holds a B.A. from Washington & Lee University.
Appointed in January 2015, David brings more than 25 years of retail, hospital, home infusion and specialty pharmacy experience to VirMedica. As executive vice president, Specialty Pharmacy Services at CVS Caremark for more than two decades, David was responsible for a robust $8 billon specialty unit during a period of extreme innovation and growth in the industry. He currently serves on the board of directors for BioScrips, Inc. and Global Healthcare Integrators, and previously served as a member of the board of directors of Salveo Specialty Pharmacy, Inc. David holds a B.S. in Pharmacy from the University of Illinois at Chicago.
Randy is a Partner and co-founder of HealthQuest Capital, a venture capital firm focused on investments into emerging companies bringing innovation to healthcare. Prior to moving into venture capital, Randy was a medtech entrepreneur. Randy currently serves on the Boards of Virmedica, Avizia Inc., and Vestagen Protective Technologies. Randy’s industry successes include starting NovaMin Technology, Inc. leading it through financing, growth and eventual acquisition by GlaxoSmithKline; a turn-around of USBiomaterials Corp, leading bone-grafting products company from perennial money-loser to a profitability (now known as NovaBone Products, LLC); and a member of the early management team at LensCrafters as it emerged from start-up to market leader. He spent the first half of his career in consumer products marketing, starting in brand management at Procter & Gamble in Cincinnati. He is a graduate of Georgia Tech.